(IN BRIEF) AstraZeneca announces the approval of Truqap (capivasertib) in combination with Faslodex (fulvestrant) by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for treating adult patients with unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer. The approval, based … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged AstraZeneca, Breast Cancer Treatment, Dave Fredrickson, Faslodex, Japan, Masakazu Toi, MHLW, safety, Truqap
(IN BRIEF) Merck, a prominent science and technology company, announces a €14 million expansion of its M LabTM Collaboration Center in Shanghai, bolstering its support for the biopharmaceutical industry in China. The expansion includes new facilities such as a biology … Read the full press release
Posted in Business, Construction, Environment, Financial, Germany, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged biopharmaceutical, CHINA, Dr. Roy Wu, M LabTM Center, Merck, partnership, Shanghai, sustainability
(IN BRIEF) DPI, BII, and the EBRD have reached a binding agreement to fully exit their investment in KELIX bio, a pan-African biopharmaceutical platform, through its acquisition by Mubadala Investment Company. Founded in 2020, KELIX bio has rapidly grown to … Read the full press release
Posted in Banks, Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Africa, Alhadi Alwazir, British International Investment (BII), Development Partners International (DPI), EBRD, Essam Farouk, Frederic Lucenet, Hocine Sidi Said, KELIX bio, Mubadala, partnership, pharmaceuticals, Samir Abhyankar, Sofiane Lahmar, sustainability
(IN BRIEF) EQT Life Sciences proudly announces Novo Nordisk’s acquisition of Cardior Pharmaceuticals, valuing the biopharmaceutical company at up to EUR 1.025 billion. Based in Hannover, Germany, Cardior specializes in RNA-based therapeutics for cardiovascular diseases, focusing initially on heart failure. … Read the full press release
Posted in Business, Denmark, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Cardior Pharmaceuticals, Christoph Broja, Claudia Ulbrich, Denmark, EQT, EQT Life Sciences, Germany, Heart Diseases, Novo Nordisk, partnership, Professor Thomas Thum, RNA Therapies, sustainability
(IN BRIEF) Ultomiris (ravulizumab-cwvz) has gained approval from the FDA as the inaugural long-acting C5 complement inhibitor for treating adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). The approval, based on the CHAMPION-NMOSD Phase III trial’s … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged Adrian Kemp, AQP4 Ab+, AstraZeneca, Marc Dunoyer, neuromyelitis optica spectrum disorder (NMOSD), safety, Sean J. Pittock, treatment, Ultomiris, USFDA
(IN BRIEF) Novartis has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorization for Fabhalta® (iptacopan) for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who … Read the full press release
(IN BRIEF) Breakpoint Therapeutics GmbH, a company focused on developing drugs targeting the DNA Damage Response (DDR), has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ), for the treatment of solid tumors. … Read the full press release
(IN BRIEF) Evonik has been honored with the Asia-Pacific Bioprocessing Excellence Award (ABEA) for the second consecutive year, specifically in the category of Best New Bioprocessing Supplier Award: Upstream Processing, for its Cell Culture Solutions portfolio. As a crucial component … Read the full press release
(IN BRIEF) EQT Life Sciences announces the acquisition of its portfolio company, Amolyt Pharma, by Alexion, AstraZeneca Rare Diseases, for a total deal value of $1.05 billion. This acquisition underscores Amolyt’s significant advancements in developing novel treatments for rare endocrine … Read the full press release
Posted in Business, Environment, European Union, Financial, Government, Healthcare, Industrial, Investment, Management, Netherlands, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged acquisition, Alexion, Amolyt Pharma, AstraZeneca Rare Diseases, Eneboparatide, EQT Life Sciences, Felice Verduyn-van Weegen, Healthcare, hypoparathyroidism, partnership, sustainability, Thierry Abribat
(IN BRIEF) The joint venture, Evonik Vland Biotech, established by Evonik China and Shandong Vland Biotech, officially commenced operations in Binzhou, China, aiming to bolster the market presence of probiotics for livestock gut health in the Greater China region while … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Animal Gut Health Solutions, Arron Chen, Dr. Xu Wang, Evonik, Evonik China and Shandong Vland Biotech, Evonik Vland Biotech, Johann-Caspar Gammelin, partnership, sustainability, Vland Group
(IN BRIEF) Evonik’s EUDRAGIT® polymers, renowned coatings for pharmaceuticals, celebrate 70 years of revolutionizing drug delivery. With over 23,000 patents and 10,000 scientific publications, these methacrylate polymers have become industry standards, employed in formulations for modified drug release across 80 … Read the full press release
Posted in Business, Chemicals, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged 70 Years, EUDRAGIT® Polymers, Evonik, INNOVATION, partnership, Paul Spencer, Pharmaceutical, sustainability, Thomas Riermeier
(IN BRIEF) Tubulis has closed an oversubscribed €128 million ($138.8 million) Series B2 financing round, co-led by EQT Life Sciences and Nextech Invest Ltd, with participation from new and existing investors including Frazier Life Sciences and Deep Track Capital. The … Read the full press release
Posted in Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged ADC Pipeline, cancer treatment, Christoph Broja, Deep Track Capital, Dominik Schumacher, EQT Life Sciences, Frazier Life Sciences, John de Koning, Kanishka Pothula, Nextech Invest Ltd, partnership, sustainability, TUB-030, TUB-040, Tubulis
(IN BRIEF) Health Canada has approved functional claims for Novonesis’ probiotic strain CLEPIUS™, acknowledging its efficacy in alleviating symptoms of irritable bowel syndrome (IBS) and improving quality of life in adults. The authorization encompasses a range of benefits, including relief … Read the full press release
Posted in Business, Denmark, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged abdominal pain, CLEPIUS™, diarrhea, Digestive Discomfort, Health Canada, irritable bowel syndrome (IBS), Jakob D. Rasmussen, Niklas Larsson, Novonesis, partnership, probiotic strain, stress, sustainability
(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release
Posted in Healthcare, Marketing, Pharma & Biotech, United Kingdom
Tagged 8th annual Patients as Partners® Europe, AbbVie, Anders Lassen, Andrew Garvey, Annie Gilbert, Astellas, AstraZeneca, Biotech, Boehringer Ingelheim, clinical operations, clinical research, clinical trials, Conference, David James, decentralized clinical trials, Derek Stewart, diversifying clinical trials, diversity, drug development, England, GSK, Health Equity, inclusivity, inclusivity in clinical research, Ipsen, LGBTQ+ oncology, Lisa Kerr, London, Lundbeck, Novartis, Novo Nordisk, Oleksandr Gorbenko, Parexel, Patient Advocacy, patient engagment, patient experience mapping, Patrick Gallogly, Pfizer, pharma, Plaisterers’ Hall, Prostate Cancer Research, Rosamund Round, Sanofi, Sarah Zenner Dolan, Stephen Head, The Conference Forum, Valerie Bowling, Victoria DiBiaso, , Alfred Samuel
(IN BRIEF) In a groundbreaking Phase 2b study, amlitelimab demonstrates remarkable potential in maintaining treatment response for patients with moderate to severe atopic dermatitis (AD). Presented at the American Academy of Dermatology (AAD) 2024 Conference, the study reveals sustained improvement … Read the full press release
(IN BRIEF) Boehringer Ingelheim and Sosei Group Corporation (Sosei Heptares) have unveiled a global collaboration and exclusive option-to-license agreement aimed at advancing the development and commercialization of Sosei Heptares’ portfolio of first-in-class GPR52 agonists. The focus of this collaboration lies … Read the full press release
Posted in Business, Education, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged Boehringer Ingelheim, GPR52 agonists, Hugh Marston, Matt Barnes, mental health, partnership, schizophrenia, Sosei Heptares, sustainability, treatment
(IN BRIEF) Fresenius Management SE has extended Sara Hennicken’s term as Chief Financial Officer (CFO) until 2027, two years earlier than planned, to ensure continuity in advancing the #FutureFresenius strategy. Hennicken, who joined Fresenius in 2019, has been instrumental in … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Management, Pharma & Biotech, Technology
Tagged #FutureFresenius, CFO, Chief Financial Officer, Deutsche Bank, finance, Fresenius, Fresenius Helios, Fresenius Kabi, Fresenius Management SE, Fresenius Medical Care, Sara Hennicken, Supervisory Board, transparency, Wolfgang Kirsch
(IN BRIEF) Fresenius Kabi announces FDA approval of Tyenne® (tocilizumab-aazg), the first tocilizumab biosimilar offering both IV and subcutaneous formulations. This marks a significant milestone in the company’s growth strategy (#FutureFresenius) and expands treatment options for inflammatory, autoimmune diseases, and … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech
Tagged #FutureFresenius, Actemra®, autoimmune diseases, Biosimilar, Cancer, cancer treatment, FDA, Food and Drug Administration, Fresenius Kabi, Genentech, Idacio®, inflammatory, inflammatory diseases, IV, IV formulation, Stimufend®, Subcutaneous formulation, subcutaneous tocilizumab biosimilar, tocilizumab, tocilizumab biosimilar, tocilizumab-aazg, Tyenne®
(IN BRIEF) GSK has announced encouraging findings from the interim analysis of the DREAMM-8 phase III trial evaluating Blenrep (belantamab mafodotin) in combination with pomalidomide plus dexamethasone (PomDex) compared to the standard of care, bortezomib plus PomDex, for relapsed or … Read the full press release
(IN BRIEF) Novo Nordisk is conducting a Capital Markets Day (CMD) to provide updates on its Strategic Aspirations 2025. The event will focus on various aspects, including corporate strategy, sustainability, research and development pipeline, and financial performance. Highlights include discussions … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Management, Media, News, Pharma & Biotech, Science, Technology
Tagged Capital Markets Day, Novo Nordisk, Strategic Aspirations 2025
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?